Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024
RANI Stock | USD 2.02 0.03 1.51% |
Under 59% of all Rani Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that some traders are interested. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
Rani |
SAN JOSE, Calif., May 09, 2024 -- Rani Therapeutics Holdings, Inc. , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
Read at benzinga.com
Rani Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
RANI: 1Q:24 Results
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rani Therapeutics Fundamental Analysis
We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Rani Therapeutics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Rani Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.
Peers
Rani Therapeutics Related Equities
CABA | Cabaletta Bio | 26.91 | ||||
SRZN | Surrozen | 19.37 | ||||
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
MNPR | Monopar Therapeutics | 8.84 | ||||
TNYA | Tenaya Therapeutics | 8.51 | ||||
VINC | Vincerx Pharma | 7.69 | ||||
BMEA | Biomea Fusion | 3.13 | ||||
VCNX | Vaccinex | 2.44 | ||||
TRVI | Trevi Therapeutics | 2.13 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
MOLN | Molecular Partners | 0.17 | ||||
TARA | Protara Therapeutics | 0.99 | ||||
ALXO | Alx Oncology | 1.99 | ||||
TYRA | Tyra Biosciences | 2.00 | ||||
PHVS | Pharvaris | 2.06 | ||||
EYPT | Eyepoint Pharmaceuticals | 2.21 | ||||
CRVS | Corvus Pharmaceuticals | 3.50 | ||||
VIRX | Viracta Therapeutics | 6.67 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |